Evidence map›Paper›PMID 22732468›Full record

Trial reportJournal of acquired immune deficiency syndromes (1999)2012

Evaluation of HIV-1 ambiguous nucleotide frequency during antiretroviral treatment interruption.

Jonathan Z Li, Julie A Christensen, Hongying Wang, John Spritzler, Daniel R Kuritzkes, AIDS Clinical Trials Group A5197 Study Team

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of acquired immune deficiency syndromes (1999), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Jonathan Z LiDivision of Infectious Diseases, Brigham and Women’s Hospital, 65 Landsdowne Street, Room 435, Cambridge, MA, USA. Jli22@partners.org
Julie A Christensen
Hongying Wang
John Spritzler
Daniel R Kuritzkes
AIDS Clinical Trials Group A5197 Study Team
Cancer Research And Biostatistics · USBrigham and Women's Hospital · USHarvard University · USOberlin College · US

Funding

AIDS Clinical Trials Group NetworkU01AI068636 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI KURITZKES, DANIEL R. · 2006 to 2010
$147.1M
The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ROBERT A. PARKER · 2004 to 2026
$94.4M
Statistical and Data Management Center for the AIDS Clinical Trials GroupU01AI068634 · NIAID · HARVARD SCHOOL OF PUBLIC HEALTH · PI HUGHES, MICHAEL DAVID · 2006 to 2010
$71.9M
Multidisciplinary HIV Training ProgramT32AI007387 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Daniel R. Kuritzkes · 1990 to 2026
$8.8M
HIV-1 THERAPEUTICS AND DRUG RESISTANCEK24RR016482 · NCRR · UNIVERSITY OF COLORADO DENVER · PI KURITZKES, DANIEL R. · 2001 to 2010
$1.0M
NCRR NIH HHS K24 RR016482NIAID NIH HHS P30 AI060354NIAID NIH HHS P30 AI60354NIAID NIH HHS T32 AI007387NIAID NIH HHS T32 AI07387NIAID NIH HHS U01 AI068634NIAID NIH HHS U01 AI068636
6 · The paper itself

Abstract

Nucleotide mixtures in human immunodeficiency virus type 1 (HIV-1) population sequences reflect sequence diversity. We evaluated gag and pol ambiguous nucleotide frequencies during an analytic treatment interruption (ATI) in an HIV-1 therapeutic vaccine study. The proportion of ambiguous nucleotides was significantly higher at ATI week 16 than at either the time of first detectable viremia (P < 0.001 gag and P = 0.03 reverse transcriptase) or preantiretroviral therapy (P = 0.007 gag). No significant differences were observed in the proportion of ambiguous nucleotides between those receiving vaccine and placebo. Increased HIV diversity during the ATI may represent a potentially higher barrier to success for a therapeutic as compared with a preventative vaccine targeting cell-mediated immunity.

Indexed as

Genetic VariationAIDS Vaccinesgag Gene Products, Human Immunodeficiency VirusHIV-1HIV InfectionsHumansImmunotherapyMolecular Sequence DataPlacebospol Gene Products, Human Immunodeficiency VirusSequence Analysis, DNAWithholding TreatmentAIDS Vaccinesgag Gene Products, Human Immunodeficiency VirusPlacebospol Gene Products, Human Immunodeficiency Virus

Identifiers

PMID22732468
PMCPMC3427424
OpenAlexW2059550815

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.